Table 4 Baseline data after propensity matching
All (31,475) | AMC (20,138) | AMX (11,337) | p-value | |
|---|---|---|---|---|
Age, median* (IQR) | 69 (62–76) | 69 (62–77) | 69 (61–76) | < 0.0001 |
Age* | 0.0008 | |||
≤ 62 | 7737 | 4823 (24%) | 2914 (26%) | |
63–69 | 7231 | 4594 (23%) | 2637 (23%) | |
70–77 | 8713 | 5644 (28%) | 3069 (27%) | |
≥ 78 | 7794 | 5077 (25%) | 2717 (24%) | |
Gender female* | 16,431 | 10,471 (52%) | 5960 (53%) | 0.33 |
FEV1* | < 0.0001 | |||
FEV1 ≥ 80% | 1942 | 1121 (6%) | 821 (7%) | |
50% ≤ FEV1 ≤ 80% | 12,774 | 7934 (39%) | 4840 (43%) | |
30% ≤ FEV1 ≤ 50% | 11,661 | 7671 (38%) | 3990 (35%) | |
FEV1 ≤ 30% | 5098 | 3412 (17%) | 1686 (15%) | |
Exacerbations within the past year* | 0 | 17,791 (88%) | 10,143 (89%) | 0.0028 |
1 | 1601 (8%) | 782 (7%) | ||
≥ 2 | 746 (4%) | 412 (4%) | ||
BMI, median* (IQR) | 25.0 (21.5–29.0) | 25.0 (21.0–29.0) | 25.0 (22.0–29.0) | < 0.0001 |
BMI* (kg/m2) | 0.0011 | |||
10.0–18.4 | 2810 | 1853 (9%) | 957 (8%) | |
18.5–24.9 | 12,308 | 7964 (40%) | 4344 (38%) | |
25.0–29.9 | 9497 | 6045 (30%) | 3452 (30%) | |
≥ 30 | 6860 | 4276 (21%) | 2584 (23%) | |
Smoking* | 0.0022 | |||
Current smokers | 10,802 | 6787 (34%) | 4015 (35%) | |
Ex-/Non-smokers | 20,673 | 13,351 (66%) | 7322 (65%) | |
Prednisolone treatment for exacerbation* | No prednisolone | 17,769 (88%) | 10,189 (90%) | < 0.0001 |
Short course treatment | 1899 (9%) | 918 (8%) | ||
Long course treatment | 470 (2%) | 230 (2%) | ||
Comorbidities | ||||
Cardiovascular disease | 10,838 | 6860 (34%) | 3978 (35%) | 0.07 |
Diabetes mellitus* | 1893 | 1165 (6%) | 728 (6%) | 0.0231 |
Renal failure | 682 | 416 (2%) | 266 (2%) | 0.11 |
Depression | 453 | 278 (1%) | 175 (2%) | 0.26 |